好看日韩在线视频免费,日本不卡一区二区三区,三级a全过程在线观看,亚洲精品国产9999久久久久

北京雅安達生物技術有限公司

當前位置:北京雅安達生物技術有限公司>>細胞生物試劑>>細胞因子>> Recombinant Human BDNF10ug(PeproTech) 編號:450-02

Recombinant Human BDNF10ug(PeproTech) 編號:450-02

參  考  價:面議
具體成交價以合同協(xié)議為準

產(chǎn)品型號

品牌

廠商性質經(jīng)銷商

所在地北京市

更新時間:2022-08-03 13:42:16瀏覽次數(shù):543次

聯(lián)系我時,請告知來自 環(huán)保在線
Recombinant Human BDNF10ug(PeproTech) 編號:450-02

 名稱:現(xiàn)貨訂購|Recombinant Human BDNF

貨號:450-02
規(guī)格:10ug
產(chǎn)地:PeproTech
Purity: BDNF is expressed as the C-terminal portion of a 247 amino acid polypeptide precursor, which also contains a signal sequence of 18 amino acid residue and a propeptide of 110 amino acid residues. Greater than 98% by SDS-PAGE gel and HPLC analyses. 
Catalog Number: 450-02 
Description: BDNF can bind to a low affinity cell surface receptor called LNGFR, which also binds other neurotrophins such as NGF, NT-3 and NT-4. However, BDNF mediates its neurotrophic properties by signaling through a high affinity cell surface receptor called gp145/trkB.  Recombinant human BDNF is a 27.0 kDa homodimer of two 119 amino acid subunits linked by strong non-covalent interactions. Human and Mouse BDNF sequences are identical. 
Biological Activity: Determined by its ability to stimulate the proliferation of rat C6 cells. The expected ED50 for this effect is 0.5-1.0 μg/ml. BDNF is a member of the NGF family of neurotrophic growth factors. Like other members of this family, BDNF supports neuron proliferation and survival.

北京 Peprotech細胞因子*,* 供應Peprotech因子

北京 Peprotech細胞因子*,* 供應Peprotech因子$r

全國直銷“Recombinant Murine VEGF165”價格

北京雅安達生物技術有限公司經(jīng)營各種*產(chǎn)品:Sigma,Amresco(

現(xiàn)貨供應“Recombinant Murine TNF-a”價格

北京雅安達生物技術有限公司經(jīng)營各種*產(chǎn)品:Sigma,Amresco(

會員登錄

×

請輸入賬號

請輸入密碼

=

請輸驗證碼

收藏該商鋪

X
該信息已收藏!
標簽:
保存成功

(空格分隔,最多3個,單個標簽最多10個字符)

常用:

提示

X
您的留言已提交成功!我們將在第一時間回復您~

以上信息由企業(yè)自行提供,信息內容的真實性、準確性和合法性由相關企業(yè)負責,環(huán)保在線對此不承擔任何保證責任。

溫馨提示:為規(guī)避購買風險,建議您在購買產(chǎn)品前務必確認供應商資質及產(chǎn)品質量。

在線留言
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |